Injection d’Herclon 440 mg

Injection d’Herclon 440 mg is a medication containing Trastuzumab, a targeted therapy used in the treatment of certain types of cancer. Trastuzumab is a monoclonal antibody that specifically targets the HER2 (human epidermal growth factor receptor 2) protein, which is overexpressed in some breast cancers and gastric cancers. By binding to HER2, Trastuzumab inhibits the growth and proliferation of cancer cells that rely on this protein for their development. It is typically administered intravenously under medical supervision.

Indications: Injection d’Herclon 440 mg is indicated for the treatment of HER2-positive breast cancer (both early-stage and metastatic) and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. It is often used in combination with other chemotherapy agents.

Dosage: The dosage and administration schedule for Injection d’Herclon 440 mg are determined by a healthcare professional based on the specific type and stage of cancer, as well as the patient’s individual response. It is crucial to follow the prescribed regimen precisely.

Side Effects: Common side effects may include fatigue, nausea, vomiting, diarrhea, headache, and fever. More serious side effects, such as heart problems (cardiotoxicity), lung problems, and severe allergic reactions, can occur. Patients should report any new or worsening symptoms to their doctor immediately.

Storage: Unused vials of Injection d’Herclon 440 mg should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Once reconstituted, the solution should be used promptly.